Table 1 Loss on R&D investment from antibiotic new molecular entity projects at small companies with FDA-approved products in recent years.
From: Changes in revenues associated with antimicrobial reimbursement reforms in Germany
Company | Location of headquarters | Current status as of April 2024 | Date of first FDA antibiotic approval | FDA-approved product | Accumulated deficit as of first FDA antibiotic approval | Market cap (calculated on April 8, 2024) or acquisition price |
|---|---|---|---|---|---|---|
Achaogen | USA | Bankrupt on 4/15/2019; has ceased operations | 6/25/2018 | Plazomicin (Zemdri) | $420,067,000 | n/a |
Entasis | USA | Now Innoviva | 5/23/2023 | Sulbactam/durlobactam (Xacduro) | $170,046,000 | $113,000,000 |
Melinta | USA | Bankrupt on 12/27/2019; now a part of Deerfield | 6/19/2017 | Delafloxacin (Baxdela) | $459,871,000 | n/a |
Nabriva | Austria | Ceased operations from 1/6/2023 | 8/19/2019 | Lefamulin (Xenleta) | $393,978,000 | $n/a |
Paratek | USA | Now a part of Novo Holdings | 10/2/2018 | Omadacycline (Nuzyra) | $559,677,000 | $462,000,000 |
Seres | USA | Active, but announced 41% reduction in force on Nov. 2, 2023 | 4/26/2023 | Fecal microbiota spores, live-BRPK (Vowst) | $935,685,000 | $110,871,000 |
Tetraphase | USA | Now La Jolla | 8/27/2018 | Eravacycline (Xerava) | $493,002,000 | $43,000,000 |
| Â | Â | Â | Â | Totals | $3,432,326,000 | $728,871,000 |
| Â | Â | Â | Â | Â | Net Loss to Date | $2,703,455,000 |
